Seattle, WA, United States
Seattle, WA, United States
SEARCH FILTERS
Time filter
Source Type

A detection and indication system for use in a railway switch machine which utilizes one or more roller members which physically interact with a point detector bar coupled to one or more switch points to provide an indication of a point failure upon movement of the point detector bar a predetermined distance from an initial position. The system includes a mounting structure structured to be coupled to a housing of the switch machine and a first sensing device coupled to the mounting structure. The first sensing device is positioned and structured to detect movement of the point detector bar a second predetermined distance from the initial position, wherein the second predetermined distance is less than the first predetermined distance.


News Article | May 10, 2017
Site: www.prnewswire.com

"Finally, we look forward to presenting the more detailed and updated global Phase 3 STS results to the medical community at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.  This Phase 3 trial, along with the combination trial of aldoxorubicin with ifosfamide/mesna, continue to build upon the body of clinical data supporting aldoxorubicin's potential as a new and better treatment for patients with STS," Mr. Kriegsman commented. Strengthened the Balance Sheet with $15 Million in Financing and $2 Million in Warrant Proceeds.  In early May 2017, CytRx completed the sale of approximately 30 million shares of common stock in a public offering at a price of $0.50 per share, resulting in net proceeds to the Company of approximately $13.9 million after deducting placement agent's fees and other estimated offering expenses.  Additionally, the Company received approximately $1.9 million from the exercise of warrants resulting in a total raise of $15.8 million subsequent to March 31, 2017. Concluded Phase 3 Trial Evaluating Aldoxorubicin in Relapsed or Refractory STS.  Based on its goal to submit a rolling NDA, subject to approval from the FDA, the Company has concluded its Phase 3 study evaluating aldoxorubicin compared to investigator's choice in patients with relapsed or refractory STS. Aldoxorubicin Clinical Trial Data in Patients with STS Selected for Oral Presentation at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO).  In April 2017, CytRx announced that an abstract describing results from its global Phase 3 clinical trial evaluating aldoxorubicin versus investigators' choice in patients with relapsed and refractory STS was selected for an oral presentation at ASCO 2017, taking place June 2-6, 2017 in Chicago.  The oral presentation (abstract #11000) will be given by Principal Investigator, Sant Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center in Santa Monica, on Friday, June 2, 2017 between 3:00-6:00 pm CT.  In addition to the STS presentation, a poster (abstract #11051) highlighting updated data from CytRx's ongoing Phase 1/2 clinical trial combining aldoxorubicin with ifosfamide/mesna in patients with first-line soft tissue sarcomas will also be presented by Frederick C. Eilber, M.D., Director of the UCLA Sarcoma Translational Research Program within the Jonsson Comprehensive Cancer Center, on Sunday, June 4, 2017 between 8:00-11:00 am CT. Announced FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in STS.  In April 2017, CytRx announced that it had reached an agreement with the FDA on the pathway for a NDA submission for aldoxorubicin as a treatment for STS.  The Company's goal is to submit a rolling NDA under section 505(b)(2) to the FDA in the fourth quarter of 2017.  The commercial launch of aldoxorubicin is projected for 2018 in the U.S.  Aldoxorubicin has received Orphan Drug Designation from the FDA for the treatment of STS, which provides for several benefits including seven years of market exclusivity after approval, certain R&D related tax credits and protocol assistance from the FDA.  CytRx also plans to discuss with the European Medicines Agency a path to filing a Marketing Authorization Application.  European regulators granted aldoxorubicin Orphan Medicinal Product Designation for STS which confers ten years of market exclusivity among other benefits. On May 2, 2017, CytRx completed a public offering of 30 million shares of its common stock at a price of $0.50 per share.  The net proceeds to CytRx from the offering, after deducting placement agent's fees and other estimated offering expenses, were approximately $13.9 million.  In addition, CytRx received $1.9 million in proceeds from the exercise of warrants in April and May 2017. Net loss for the quarter ended March 31, 2017, was $11.0 million, or $(0.10) per share, compared with a net loss of $12.6 million, or $(0.19) per share, for the quarter ended March 31, 2016.  During the first quarter of 2017, the Company recognized a non-cash loss of $0.03 million on the fair value adjustment of warrant derivative liability related to warrants issued in 2016, compared to a non-cash loss of $0.2 million during the first quarter of 2016 related to now expired warrants. Research and development (R&D) expenses were $6.8 million for the first quarter of 2017, and included development expenses of $4.0 million for aldoxorubicin, approximately $0.6 million for pre-clinical development of new albumin-binding, ultra-high potency cancer drugs (German lab), and approximately $2.2 million for general operation of our clinical programs.  R&D expenses were $8.2 million for the first quarter of 2016. General and administrative (G&A) expenses were $3.0 million for the first quarter of 2017, compared with $4.0 million for the first quarter of 2016. CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin.  CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies. This press release contains forward-looking statements. Such statements are not promises or guarantees, and involve numerous risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements.  These risks include: the timing and final results of CytRx's clinical testing of aldoxorubicin; timing of CytRx's preparation and submission of an NDA for aldoxorubicin for the treatment of STS and FDA acceptance and review of any NDA; the risk that CytRx may be unsuccessful in obtaining FDA approval or, if approval is obtained, in commercializing aldoxorubicin in the United States or elsewhere; risks related to CytRx's need for and ability to raise additional capital or enter into strategic partnerships to fund its ongoing working capital needs and development efforts; risks related to CytRx's ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements; risks relating to preclinical testing of CytRx's LADR™ linker technology platform; risks related to pending lawsuits against CytRx and its officers and directors; and the other risks and uncertainties described in CytRx's Annual Report on Form 10-K for the year ended December 31, 2016 filed with the Securities and Exchange Commission. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytrx-reports-first-quarter-2017-financial-results-300455045.html


A method of testing a target electronic device implemented in a configurable integrated circuit device includes receiving a baseline design for the target electronic device in a hardware description language, establishing a fault model for the particular configurable integrated circuit device, synthesizing the fault model in the hardware description language, embedding the synthesized fault model into the baseline design to create a modified baseline design in the hardware description language which enables one or more targeted signals to be selectively corrupted, creating a fault model enabled target device on the particular configurable integrated circuit device using the modified baseline design, performing a number of fault injection experiments on the fault model enabled target device, wherein each fault injection experiment includes causing at least one of the one or more targeted signals to be corrupted within the fault model enabled target device.


Patent
STS Inc | Date: 2011-07-29

An embodiment of a power supply includes an input node, a converter stage, and an outlet. The input node is operable to receive an input AC signal having peak portions and non-peak portions. The converter stage is operable to generate a DC power signal from the input AC signal and to cause a first current to be drawn from the input node during at least the non-peak portions of the input AC signal. And the outlet is operable to carry the DC power signal. For example, such a power supply may be installed in a facility such as a residence, office building, or manufacturing plant, or the facilitys existing power supply may be retrofitted, to provide one or more power outlets that each carry a respective power-factor-corrected (PFC) DC voltage. Because the outlet voltages are PFC voltages, the amount of wasted power dissipated in the facility power lines/wiring and in the main power lines from the power company may be significantly reduced, without requiring each piece of equipment (e.g., an appliance, machinery) that is wired/plugged into the outlets to have an onboard PFC. This savings in wasted power may provide a significant cost savings to both the facility owner (e.g., lower electric bill) and the power company (e.g., lower power-generation and grid costs), and the ability to use equipment lacking onboard PFCs may reduce the purchase price of the equipment.


A detection and indication system for use in a railway switch machine which utilizes one or more roller members which physically interact with a point detector bar coupled to one or more switch points to provide an indication of a point failure upon movement of the point detector bar a predetermined distance from an initial position. The system includes a mounting structure structured to be coupled to a housing of the switch machine and a first sensing device coupled to the mounting structure. The first sensing device is positioned and structured to detect movement of the point detector bar a second predetermined distance from the initial position, wherein the second predetermined distance is less than the first predetermined distance.


A method of adjusting one or more of braking parameters used in a braking function to control braking of a train includes determining an adjustment factor based on a joint stopping distance probability distribution, the joint stopping distance probability distribution representing the composite effect on stopping distance of a plurality of predetermined train characteristic parameters, each of the predetermined train characteristic parameters being variable, and applying the adjustment factor to each of the one or more of braking parameters. Also, a method of adjusting braking parameters that includes determining an adjustment factor based on a nominal value, a worst case limit value and a best case limit value of each of a plurality of predetermined train characteristic parameters, each of the predetermined train characteristic parameters being variable, and applying the adjustment factor to each of the one or more of braking parameters.


A railroad monitoring apparatus includes first and second diverse vital processing units, first and second current sensors configured to measure the current being provided to one or more signaling elements of an item of wayside signaling equipment, and means for measuring voltage levels being supplied to each of the signaling elements. The first processing unit receives a first current measurement from the first current sensor and the measured voltage levels, and the second vital processing unit receives a second current measurement from the second current sensor and the measured voltage levels. The vital processing units are each programmed to determine based on one or more of the first current measurement, the second current measurement and the measured voltage levels: (i) the state of the item of railroad wayside signaling equipment, (ii) failures within the item of railroad wayside signaling equipment, and (iii) failures within the monitoring apparatus itself.


Patent
STS Inc | Date: 2012-05-24

An electronic amplifier includes a configurable integrated circuit device structured to synthesize at least a first signal and a second signal, scale the first signal to create a scaled first signal and scale the second signal to create a scaled second signal, create a discrete time composite signal which comprises a summation of at least the scaled first signal and the scaled second signal, create a discrete time pulse width modulated signal based on the discrete time composite signal, and generate a number of control signals based on the discrete time pulse width modulated signal. The electronic amplifier also includes a power switching stage receiving the number of control signals from the configurable integrated circuit device, wherein the number of control signals are configured to control the power switching stage, and a low pass filter coupled to an output of the power switching stage.


A sequential monitoring system is for an interlocking logic system and a track circuit system including a plurality of track circuits. The sequential monitoring system includes an interface between the interlocking logic system and the track circuit system; and a processor structured to monitor a state of each of the track circuits, validate a sequence of state changes of the track circuits, and interrupt and correct invalid track circuit state indications between the track circuit system and the interlocking logic system. The interface normally passes inputs from the track circuit system to outputs to the interlocking logic system. When an out of sequence event occurs, the processor applies a quarantine to a minimum of three of the track circuits in a quarantined area, thereby inhibiting use of an unoccupied track circuit in the quarantined area.


Patent
STS Inc | Date: 2014-02-11

A method of controlling braking of a train that includes obtaining in an on-board computer of the train a brake propagation delay time (T_(d)), a brake build-up time (T) and a maximum brake rate (_(max)) for the train, and controlling braking of the train in the on-board computer by generating one or more braking signals for the train using T_(d), T and _(max). Also, a methods of determining for a train a profile velocity to a target position of a selected target, selecting a most restrictive target from among a plurality of targets for a train, and determining a plurality of braking parameters for a train having a train consist, wherein the parameters include a brake propagation delay time (T_(d)), a brake build-up time (T) and a maximum brake rate (_(max)).

Loading STS Inc collaborators
Loading STS Inc collaborators